BioCentury | Dec 15, 2020
Finance

Dec. 14 Quick Takes: Locanabio raises $100M series B; plus rare bleeding disorder newco Hemab, raises for Rani, CG, InnoSkel, Denovo, Biosion and more

...company's shareholders, including the Elliott Advisors Ltd. affiliate of Elliott Management Corp. TARGETSTSLP – Thymic stromal lymphopoietin BC Staff CG0070 HTD1801 Locanabio Inc. Vida...
BioCentury | Sep 24, 2020
Emerging Company Profile

Libra launches with $29M, three neurodegeneration programs to lower toxic protein levels

...a preclinical antisense oligo for ALS and FTD. Locana...
BioCentury | Sep 19, 2020
Translation in Brief

Gene therapies from Passage Bio, Locanabio; Lava’s antitumor bispecific, health disparities in Alzheimer’s and more

...kinaseGRN – GranulinPGRN (PCDGF) - Progranulin TCR – T cell receptor Danielle Golovin PBFT02 Passage Bio Inc. University of Pennsylvania Locana...
BioCentury | Apr 4, 2020
Management Tracks

CureVac names Stéphenne chairman; plus Desmond-Hellmann to Pfizer’s board, Reagan-Udall, Kyowa Kirin, Assembly, BioCryst and more

...of drug regulatory affairs at the Novartis Pharma China unit of Novartis AG (NYSE:NVS; SIX:NOVN). Locana...
...company raised $55 million in a May series A to target repeat expansion diseases (see "Locana...
...CMO. He was director of rare disease development at Orion Corp. (HSE:ORNAV; HSE:ORNBV). Robin Sawka, BioCentury Staff Locana...
BioCentury | Dec 11, 2019
Company News

Management tracks: Elevate hires CSO of regenerative medicine; plus BridgeBio, Acceleron, Flexion, Locana, Nkarta and more

...plans to seek a new CSO. James Burns will succeed Jeffrey Ostrove as CEO of Locana...
...Elizabeth S. Eaton, Staff Writers BridgeBio Pharma Inc. Acceleron Pharma Inc. Replimune Group Inc. Stemline Therapeutics Inc. Nkarta Inc. Muscular Dystrophy Association Locana...
BioCentury | Sep 5, 2019
Company News

Management tracks: Locana, Synlogic, Farcast, Oncology Venture, Cala, Novaremed, Sidley Austin and Logos Capital

...when it also hired gene therapy veteran and board member Jeffrey Ostrove as CEO (see “Locana...
...according to his LinkedIn page. He previously was a principal with Versant Ventures. BioCentury Staff Cala Health Inc. Locana Novaremed...
BioCentury | May 23, 2019
Finance

With new CEO, $55M A round, Locana readies RNA-targeting gene therapy for clinic

...Preclinical data supporting its RNA-targeting gene therapy platform enabled Locana to attract $55 million in series...
...to use to bring its first therapy into the clinic for genetic repeat expansion diseases. Locana...
...it may be less applicable to expansion repeat diseases than Locana’s approach. Ostrove added that Locana’s...
BioCentury | Oct 4, 2018
Tools & Techniques

No crisp upper hand in CRISPR

...which Sherkow says also falls beyond the scope of the initial UC and Broad patents. Locana...
...Genomics Ltd., Dublin, Ireland Excision BioTherapeutics Inc., Philadelphia, Pa. Intellia Therapeutics Inc. (NASDAQ:NTLA), Cambridge, Mass. Locana...
BioCentury | Mar 16, 2018
Preclinical News

New Cas enzyme can edit RNA, target tau

...only company that has disclosed use of CRISPR to target RNA for therapeutic purposes is Locana...
...system to bind and destroy RNA (see BioCentury Innovations, Sept. 14, 2017) . Sandi Wong Arbor Biotechnologies Inc. Locana...
BioCentury | Jan 18, 2018
Translation in Brief

Editing translation

...In 2016, Locana Inc. was launched with a CRISPR-Cas system designed to edit RNA targets. Locana’s...
Items per page:
1 - 10 of 14
BioCentury | Dec 15, 2020
Finance

Dec. 14 Quick Takes: Locanabio raises $100M series B; plus rare bleeding disorder newco Hemab, raises for Rani, CG, InnoSkel, Denovo, Biosion and more

...company's shareholders, including the Elliott Advisors Ltd. affiliate of Elliott Management Corp. TARGETSTSLP – Thymic stromal lymphopoietin BC Staff CG0070 HTD1801 Locanabio Inc. Vida...
BioCentury | Sep 24, 2020
Emerging Company Profile

Libra launches with $29M, three neurodegeneration programs to lower toxic protein levels

...a preclinical antisense oligo for ALS and FTD. Locana...
BioCentury | Sep 19, 2020
Translation in Brief

Gene therapies from Passage Bio, Locanabio; Lava’s antitumor bispecific, health disparities in Alzheimer’s and more

...kinaseGRN – GranulinPGRN (PCDGF) - Progranulin TCR – T cell receptor Danielle Golovin PBFT02 Passage Bio Inc. University of Pennsylvania Locana...
BioCentury | Apr 4, 2020
Management Tracks

CureVac names Stéphenne chairman; plus Desmond-Hellmann to Pfizer’s board, Reagan-Udall, Kyowa Kirin, Assembly, BioCryst and more

...of drug regulatory affairs at the Novartis Pharma China unit of Novartis AG (NYSE:NVS; SIX:NOVN). Locana...
...company raised $55 million in a May series A to target repeat expansion diseases (see "Locana...
...CMO. He was director of rare disease development at Orion Corp. (HSE:ORNAV; HSE:ORNBV). Robin Sawka, BioCentury Staff Locana...
BioCentury | Dec 11, 2019
Company News

Management tracks: Elevate hires CSO of regenerative medicine; plus BridgeBio, Acceleron, Flexion, Locana, Nkarta and more

...plans to seek a new CSO. James Burns will succeed Jeffrey Ostrove as CEO of Locana...
...Elizabeth S. Eaton, Staff Writers BridgeBio Pharma Inc. Acceleron Pharma Inc. Replimune Group Inc. Stemline Therapeutics Inc. Nkarta Inc. Muscular Dystrophy Association Locana...
BioCentury | Sep 5, 2019
Company News

Management tracks: Locana, Synlogic, Farcast, Oncology Venture, Cala, Novaremed, Sidley Austin and Logos Capital

...when it also hired gene therapy veteran and board member Jeffrey Ostrove as CEO (see “Locana...
...according to his LinkedIn page. He previously was a principal with Versant Ventures. BioCentury Staff Cala Health Inc. Locana Novaremed...
BioCentury | May 23, 2019
Finance

With new CEO, $55M A round, Locana readies RNA-targeting gene therapy for clinic

...Preclinical data supporting its RNA-targeting gene therapy platform enabled Locana to attract $55 million in series...
...to use to bring its first therapy into the clinic for genetic repeat expansion diseases. Locana...
...it may be less applicable to expansion repeat diseases than Locana’s approach. Ostrove added that Locana’s...
BioCentury | Oct 4, 2018
Tools & Techniques

No crisp upper hand in CRISPR

...which Sherkow says also falls beyond the scope of the initial UC and Broad patents. Locana...
...Genomics Ltd., Dublin, Ireland Excision BioTherapeutics Inc., Philadelphia, Pa. Intellia Therapeutics Inc. (NASDAQ:NTLA), Cambridge, Mass. Locana...
BioCentury | Mar 16, 2018
Preclinical News

New Cas enzyme can edit RNA, target tau

...only company that has disclosed use of CRISPR to target RNA for therapeutic purposes is Locana...
...system to bind and destroy RNA (see BioCentury Innovations, Sept. 14, 2017) . Sandi Wong Arbor Biotechnologies Inc. Locana...
BioCentury | Jan 18, 2018
Translation in Brief

Editing translation

...In 2016, Locana Inc. was launched with a CRISPR-Cas system designed to edit RNA targets. Locana’s...
Items per page:
1 - 10 of 14